Fresh off of a $15 million private placement and restructuring transaction intended to simplify its capital structure, WaferGen Biosystems has shifted its focus to position itself as a provider of tools to supplement next-generation sequencing.

Specifically, the company plans to use its recent funding and newfound financial flexibility to increase sales and marketing efforts for its SmartChip real-time PCR system as a tool for target enrichment upstream and biomarker validation downstream of NGS, microarray analysis, or other molecular discovery methods.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.